ArticleEBioMedicine2017
Transcriptome Analysis Uncovers a Growth-Promoting Activity of Orosomucoid-1 on Hepatocytes.
Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Transglutaminase 2 regulates vimentin-dependent proteostasis during macrophage activation.Science advances · 2026Article
- Proteome characterization of liver-kidney comorbidity after microbial sepsis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor.Cell death discovery · 2023Article
- Targeting transglutaminase 2 mediated exostosin glycosyltransferase 1 signaling in liver cancer stem cells with acyclic retinoid.Cell death & disease · 2023Article
- ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma.Bosnian journal of basic medical sciences · 2022Article
- Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma.Scientific reports · 2022Article
- A reference single-cell regulomic and transcriptomic map of cynomolgus monkeys.Nature communications · 2022Article
- Interval-Based Secretomics Unravels Acute-Phase Response in Hepatocyte Model Systems.Molecular & cellular proteomics : MCP · 2022Article
- Comprehensive analysis of the cancer driver genes constructs a seven-gene signature for prediction of survival and tumor immunity in hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Identification of gene signature in RNA-Seq hepatocellular carcinoma data by Pareto-optimal cluster algorithm.Gastroenterology and hepatology from bed to bench · 2022Article
- Orosomucoid in liver diseases.World journal of gastroenterology · 2021Article
- Inhibition of Ganglioside Synthesis Suppressed Liver Cancer Cell Proliferation through Targeting Kinetochore Metaphase Signaling.Metabolites · 2021Article
- Into the Labyrinth of the Lipocalin α1-Acid Glycoprotein.Frontiers in physiology · 2021Review
- Cancer classification based on chromatin accessibility profiles with deep adversarial learning model.PLoS computational biology · 2020Article
- Early Transcriptomic Changes upon Thalidomide Exposure Influence the Later Neuronal Development in Human Embryonic Stem Cell-Derived Spheres.International journal of molecular sciences · 2020Article
- Lipid desaturation-associated endoplasmic reticulum stress regulates MYCN gene expression in hepatocellular carcinoma cells.Cell death & disease · 2020Article
- Non-Genomic Control of DynamicFrontiers in oncology · 2020Review
- Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation.Scientific reports · 2019Article
- Arachidonic acid suppresses hepatic cell growth through ROS-mediated activation of transglutaminase.FEBS open bio · 2018Article
- Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 11 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acute phase protein orosomucoid-1 (Orm1) is mainly expressed by hepatocytes (HPCs) under stress conditions. However, its specific function is not fully understood. Here, we report a role of Orm1 as an executer of HPC proliferation. Increases in serum levels of Orm1 were observed in patients after surgical resection for liver cancer and in mice undergone partial hepatectomy (PH). Transcriptome study showed that Orm1 became the most abundant in HPCs isolated from regenerating mouse liver tissues after PH. Both in vitro and in vivo siRNA-induced knockdown of Orm1 suppressed proliferation of mouse regenerating HPCs and human hepatic cells. Microarray analysis in regenerating mouse livers revealed that the signaling pathways controlling chromatin replication, especially the minichromosome maintenance protein complex genes were uniformly down-regulated following Orm1 knockdown. These data suggest that Orm1 is induced in response to hepatic injury and executes liver regeneration by activating cell cycle progression in HPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.